Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $18,804 | $11,265 | $12,267 | $9,732 |
| - Cash | $0 | $6,229 | $7,004 | $4,976 |
| + Debt | $0 | $989 | $902 | $536 |
| Enterprise Value | $18,804 | $6,025 | $6,165 | $5,292 |
| Revenue | $172 | $14 | $58 | $44 |
| % Growth | 1,128.6% | -75.9% | 31.8% | – |
| Gross Profit | $169 | $5 | $33 | -$397 |
| % Margin | 98.3% | 35.7% | 56.9% | -902.3% |
| EBITDA | -$2,832 | -$2,789 | -$4,468 | -$4,418 |
| % Margin | -1,646.5% | -19,921.4% | -7,703.4% | -10,040.9% |
| Net Income | -$2,780 | -$3,044 | -$4,708 | -$3,740 |
| % Margin | -1,616.3% | -21,742.9% | -8,117.2% | -8,500% |
| EPS Diluted | -0.067 | -0.12 | -0.16 | -0.17 |
| % Growth | 44.1% | 25% | 5.9% | – |
| Operating Cash Flow | – | -$2,831 | -$6,871 | -$8,331 |
| Capital Expenditures | – | $0 | -$583 | -$350 |
| Free Cash Flow | – | -$2,831 | -$7,454 | -$8,681 |